INDOLE AND INDAZOLE COMPOUNDS AS CELLULAR NECROSIS INHIBITORS Russian patent published in 2011 - IPC C07D417/04 C07D231/56 C07D401/02 A61K31/454 A61K31/541 A61P1/16 A61P3/10 A61P9/00 A61P25/16 A61P25/28 A61P31/00 A61P35/00 

FIELD: chemistry.

SUBSTANCE: invention relates to indole and indazole compounds of formula in which n equals a whole number from 1 to 3, m equals 0 or 1, A denotes phenyl, X denotes C or N, R¹ denotes hydrogen, alkyl, -(CH₂)_rNR⁷R⁸, where r equals a whole number from 1 to 5, and R⁷ and R⁸ independently denote hydrogen, alkyl or alkylcarbonyl, or can together form an optionally alkyl-substituted alkylene chain, where optionally one methylene is substituted with a N atom, R² denotes hydrogen, halogen, cyano, nitro, hydroxy, alkyl, alkoxy or trialkylsilyl, denotes -(CH₂)_pCO₂R⁷, -(CH₂)_pOR⁷, -(CH₂)_pNR⁷R⁸, -NHR¹⁰, -N(H)S(O)₂R⁷, -NHC(O)R¹⁰, -(CH₂)_pS(O)₂R⁷ or (CH₂)_p-heterocycle-R¹⁰, where p equals a whole number from 0 to 3, R⁷ and R⁸ are as defined above, R¹⁰ denotes hydrogen, oxo, alkylsulphonyl, alkylcarbonyl, alkyloxycarbonyl, alkoxy, alkyl or heterocycle, R³ denotes hydrogen, cyano, halogen, alkyl or phenyl, or denoes -(CH₂)_n-heterocycle or -(CH₂)_n-aryl, where n equals a whole number from 0 to 3, provided that R³ denotes phenyl when X denotes C and m=0, R⁴ denotes -YR¹¹, where Y denotes a direct bond or -(CR⁷R⁸)_pY′-, where p equals a whole number from 0 to 3, R⁷ and R⁸ are as defined above, Y′ is selected from a group consisting of -O-, -S-, -NR¹²-, -NR¹²C(O)-, -C(O)-, -C(O)O-, -C(O)NR¹²-, -S(O)_q- and -S(O)_qNR¹²-, where R¹² denotes hydrogen, alkyl, aryl or heteroaryl, q equals a whole number from 0 to 2, R¹¹ is selected from a group consisting of hydrogen, cyano, halogen, hydroxy, thiol, carboxy, alkyl and -(CH₂)_tB-R¹³, where t equals a whole number from 0 to 3, B denotes heterocycle, heteroaryl or aryl, R¹³ denotes hydrogen, cyano, halogen, hydroxy, oxo, thiol, carboxy, carboxyalkyl, alkylcarbonyloxy, alkyl, alkoxy, alkylthio, alkylcarbonyl or alkylsulphonyl, R⁵ denotes hydrogen, alkyl, cycloalkyl, heterocycle or heterocyclylalkyl, R⁶ denotes (CR⁷R⁸)_p-Z-D-W-R¹⁴, where Z denotes a direct bond, or is selected from a group consisting of -C(O)-, -C(O)O, -C(O)NR¹²- and -S(O)_y-, y equals a whole number from 1 or 2, D denotes a direct bond, or denotes cycloalkyl, heteroaryl or heterocycle, W denotes a direct bond, or denotes -NR -, -C(O)-, -C(O)O-, -C(O)NR¹²-, -S(O)_y-, -S(O)_yNR¹²- or -NR¹²S(O)_y, wherein R¹⁴ denotes hydrogen, hydroxy, alkyl, alkoxy, heterocycle, heteroaryl, aryl or aralkyl, R⁵ and R⁶ together denote an alkylene chain, provided that R⁶ denotes cycloalkyl or heterocyclyl when X denotes N, where the heteroaryl is a 5-6-member aromatic ring containing 1-2 heteroatoms selected from N, O and S, the heterocycle is a 3-8-member ring containing 1-3 heteroatoms selected from N, O and S, where the alkyl, alkoxy, aryl, cycloalky, heterocycle and heteroaryl can be optionally substituted, and the substitutes, one or more, are selected from a group consisting of hydroxy, halogen, nitrile, amino, alkylamino, dialkylamino, carboxy, alkyl, alkoxy, carboxyalkyl, alkylcarbonyloxy, alkylthio, alkyloxycarbonyl, alkylaminocarbonyl, arylalkoxy and oxo, and pharmaceutically acceptable salts or stereoisomers thereof. The invention also relates to a composition, as well as a method of preparing said composition.

EFFECT: obtaining novel biologically active compounds for preventing or treating necrosis and necrosis-associated diseases.

40 cl, 162 ex, 2 tbl